FDA

The go-ahead for Alnylam Pharmaceuticals–partnered Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
In this episode of Denatured, you’ll hear from Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take to turn existing molecules into viable new therapies.
Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.
Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
FDA
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
PRESS RELEASES